Pregnant Patient with Penicillin Allergy Label Needing Group B Streptococcus Prophylaxis
A 31-year-old woman at 37 weeks' gestation is GBS-positive and requires intrapartum antibiotic prophylaxis. Her chart lists 'penicillin allergy' from childhood: her mother reports a rash at age 4, no details, no hospitalization, no swelling, no breathing difficulty. She has since taken amoxicillin once for a dental infection at age 20 without reaction, but the label was never removed. She is anxious about anaphylaxis during labor and asks whether she can 'just have clindamycin' instead. She has no other allergies and no history of asthma.
1. How do you risk-stratify this penicillin label, and what is the preferred management?
Read the worked answer
This is a low-risk penicillin label: a childhood rash of unknown type, no systemic features, no hospitalization, and - critically - a subsequent tolerated amoxicillin course. The tolerated re-exposure is strong evidence against a current IgE-mediated penicillin allergy, though it does not formally exclude a delayed reaction. The preferred management is to remove the label, ideally via direct oral challenge (or, given she is in late pregnancy, a supervised test dose/challenge with resuscitation available) rather than accepting the label and using an alternative.
The reasoning matters because the alternative (clindamycin) is not equivalent: clindamycin is less effective for GBS prophylaxis, has higher rates of resistance among GBS isolates, and is associated with Clostridioides difficile risk. Penicillin is the preferred agent. So the correct answer is to challenge/remove the label and use penicillin, not to accept the label and use clindamycin.
2. If the patient refuses testing and insists on clindamycin, what must you verify, and what are the consequences of that choice?
Read the worked answer
If she declines testing, you must (1) verify GBS susceptibility to clindamycin - if the isolate is clindamycin-resistant, clindamycin is not appropriate and an alternative (e.g., vancomycin based on susceptibility) is needed; (2) document the informed refusal and the rationale; (3) recognize that clindamycin is a second-line agent with lower efficacy for GBS prophylaxis and higher resistance rates, so the infant's risk of early-onset GBS disease is higher than with penicillin.
The judgment being tested is that 'respect the patient's preference' does not mean 'stop thinking.' The clinician should counsel that the label is likely false, that a challenge is low-risk given the tolerated amoxicillin, and that declining it has a measurable downside for the neonate. If she still refuses, the plan must include susceptibility verification and clear documentation.